Press Release: Vanda Pharmaceuticals Inc. – 14 hours ago
WASHINGTON, May 23, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (VNDA) today announced that the company has been named the 2013 Life Science Firm of the Year by the Tech Council of Maryland (TCM). Vanda was honored at the TCM's 25th Annual Tech Awards Celebration held in Bethesda, Maryland. The Tech Awards Celebration recognizes the leaders and innovators in the technology and life science communities in Maryland and the surrounding regions.
"We are deeply honored to receive this recognition from the Tech Council of Maryland," said Mihael H. Polymeropoulos, M.D., President and CEO of Vanda. "We are privileged to work in a region that is supportive of our efforts to develop new treatments designed to improve the lives of others."
In selecting Vanda for this award, the TCM recognized Vanda's commitment to address patient needs and the company's work to develop tasimelteon, a circadian regulator, for the treatment of Non-24-Hour Disorder (Non-24). Vanda recently announced positive results in the SET and RESET Phase III efficacy studies for Non-24. Non-24 is a serious, rare circadian rhythm disorder that affects a majority of totally blind individuals. Currently no treatment for Non-24 has been approved by the U.S. Food and Drug Administration (FDA). Vanda is targeting a New Drug Application submission with the FDA for tasimelteon in mid-2013.
About The Tech Council of Maryland
The Tech Council of Maryland (TCM) is the largest technology trade group serving the advanced technology and biotechnology communities of Maryland. TCM's mission is to advocate for the interests of the technology community, further the role of technology in the Maryland economy, and nurture an environment where technology companies can collaborate, grow and succeed. For more information, visit www.techcouncilmd.com.
Recent VNDA News
- Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend] • Edgar (US Regulatory) • 08/08/2024 11:47:27 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:29:01 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 11:01:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 08:05:32 PM
- Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results • PR Newswire (US) • 07/31/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/29/2024 09:24:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/29/2024 09:21:33 PM
- Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024 • PR Newswire (US) • 07/26/2024 01:19:00 PM
- Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex • PR Newswire (US) • 07/01/2024 12:01:00 PM
- Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders • PR Newswire (US) • 06/20/2024 12:48:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:38:04 PM
- Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak • PR Newswire (US) • 06/13/2024 02:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:30:57 PM
- Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd. • PR Newswire (US) • 06/06/2024 01:24:00 PM
- Vanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference • PR Newswire (US) • 05/30/2024 09:20:00 PM
- Vanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY® • PR Newswire (US) • 05/30/2024 08:48:00 PM
- Vanda Pharmaceuticals Announces Presentations at SLEEP 2024 • PR Newswire (US) • 05/29/2024 06:17:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:49:41 PM
- Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders • PR Newswire (US) • 05/24/2024 08:46:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:43:11 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/24/2024 08:31:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:55:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:53:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:52:54 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/21/2024 08:34:42 PM
FEATURED Mawson Finland Provides Update on Exploration Activities at Rajapalot • Aug 21, 2024 9:06 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM